Zhengye Biotechnology Holding Limited (ZYBT) Earnings History
Profitable4 years of earnings data (2021–2024) · Positive TTM net income
Loading earnings history...
Zhengye Biotechnology Holding Limited (ZYBT) Earnings Overview
As of June 30, 2026, Zhengye Biotechnology Holding Limited (ZYBT) reported trailing twelve-month net income of $11M. The company earned $0.00 per diluted share over the past four quarters, with a net profit margin of 6.1%.
Looking at the long-term picture, ZYBT's historical earnings data spans multiple years. The company achieved its highest annual net income of $47M in fiscal 2022.
Zhengye Biotechnology Holding Limited maintains positive profitability with a gross margin of 49.0%, operating margin of 8.8%, and net margin of 6.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ATXG (-$7M net income, -83.2% margin), CLPS (-$9M net income, -4.3% margin), TAOP (-$7M net income, -32.7% margin), ZYBT has outperformed on profitability metrics. Compare ZYBT vs ATXG →
ZYBT Earnings vs Peers
Earnings metrics vs comparable public companies
ZYBT Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $11M | -64.0% | $16M | $0.00 | 6.1% | 8.8% |
| 2023 | $31M | -32.7% | $45M | $0.00 | 14.9% | 21.3% |
| 2022 | $47M | +20.0% | $66M | $0.00 | 18.0% | 25.3% |
| 2021 | $39M | - | $52M | $0.00 | 18.2% | 24.5% |
Download Data
Export ZYBT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZYBT — Frequently Asked Questions
Quick answers to the most common questions about buying ZYBT stock.
What is ZYBT earnings per share (EPS)?
ZYBT trailing twelve-month (TTM) diluted EPS is $0.00, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2024 is available in the table on this page.
What is Zhengye Biotechnology Holding Limited's net income?
Zhengye Biotechnology Holding Limited (ZYBT) trailing twelve-month net income is $11M as of 2024. Earnings declined N/A year-over-year. Zhengye Biotechnology Holding Limited has been profitable for 4 consecutive years.
Is ZYBT profitable?
Yes, ZYBT is profitable with a TTM net income of $11M and a net profit margin of +6.1%. Zhengye Biotechnology Holding Limited has generated profits for 4 consecutive years.
What is ZYBT's earnings growth rate?
ZYBT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2024.
What are ZYBT's profit margins?
Zhengye Biotechnology Holding Limited net profit margin is +6.1%, operating margin is +8.8%, and gross margin is +49.0%. Margins are within a typical range for the sector. Return on Equity is +3.3%.
Is ZYBT growing earnings?
ZYBT TTM EPS: $0.00. Net income: $11M. YoY earnings change: N/A.
What was ZYBT's best earnings year?
Zhengye Biotechnology Holding Limited's highest annual net income on record is $47M, achieved in fiscal year 2022. Earnings history on this page spans 2021 to 2024 and includes all annual and quarterly figures.